BMS 986189Alternative Names: BMS-986189; BMS-986189-07
Latest Information Update: 19 Apr 2016
At a glance
- Originator Bristol-Myers Squibb
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Sepsis
Most Recent Events
- 14 Apr 2016 Bristol-Myers Squibb plans a phase I pharmacokinetics trial in Healthy volunteers in USA (unspecified) (NCT02739373)
- 08 Apr 2016 Preclinical trials in Sepsis in USA (unspecified route) before April 2016